Indivior (INDV)

• Market cap: $3.03B
• 1 day: -1.27%
• 5 days: 2.78%
• 1 month: 40.08%
• 3 months: 102.96%
• 6 months: 190.68%
• Year to date: 92.08%
• 1 year: 92.85%
• 5 years: 5.45%
• 10 years: 5.45%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.

Employees: 1,164

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,026% more call options, than puts

Call options by funds: $4.21M | Put options by funds: $374K

150% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 10 (+6) [Q2]

95% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 22

81% more capital invested

Capital invested by funds: $866M [Q1] → $1.57B (+$703M) [Q2]

16% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 32

12.04% more ownership

Funds ownership: 73.22% [Q1] → 85.26% (+12.04%) [Q2]

2% more funds holding

Funds holding: 114 [Q1] → 116 (+2) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 17% downside
• Avg. target: $23 3% downside
• High target: $28 17% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Brandon Folkes	17% upside $28	Buy Initiated	6 Aug 2025
Jefferies Dennis Ding	17% downside $20	Buy Assumed	22 Jul 2025
Craig-Hallum Chase Knickerbocker	8% downside $22	Buy Maintained	30 Jun 2025